Alvogen acquires leading nasal spray device in Russia
The Dolphin brand is currently the third largest on the Russian market for nasal rinsing.
Alvogen has acquired a leading nasal spray device in Russia, sold under the Dolphin brand. The product is designed for full rinsing of the nasal cavity and helps in the prevention of flu and the alleviation of common cold symptoms.
The Dolphin brand is currently the third largest on the Russian market for nasal rinsing and has become highly popular amongst consumers due to the proven effectiveness of its products. Nasal rinsing is part of Cough and Cold, the largest over-the-counter (OTC) segment in Russia, which accounts for more than 25% of the total OTC market.
Alvogen Russia has gradually been expanding its portfolio in Russia with the acquisition of Dolphin further strengthening and diversifying Alvogen’s OTC portfolio in the market. With over 30 products currently on the market, the company’s OTC portfolio consists of the following four main categories:
In addition to the Alvogen over-the-counter segment, the company offers a strong line in women’s healthcare with its hormone portfolio as well as in the cardiovascular field via portfolio of nitrates products acquired recently from Belgium’s UCB.
Commenting on the transaction, Alexander Vinogradov, country manager for Alvogen Russia, said: “The acquisition of Dolphin further diversifies our local portfolio and enhances our platform for continued growth across the region. Russia remains one of the most attractive markets for our business in the CEE region.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.